| Issue |
Section |
Title |
File |
| Vol 22, No 2 (2020) |
Best Practice |
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience |
(Rus)
(Eng)
|
| Vol 23, No 1 (2021) |
CLINICAL ONCOLOGY |
Opportunities for metastatic triple negative breast cancer therapy |
(Rus)
|
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
The consensus on the prevention and correction of hyperglycemia in patients with HR+ HER2- metastatic breast cancer treated with alpelisib |
(Rus)
|
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
Novel therapeutic strategies for patients with metastatic triple-negative breast cancer |
(Rus)
|
| Vol 22, No 4 (2020) |
CLINICAL ONCOLOGY |
Improving early breast cancer treatment: the role of granulocyte colony-stimulating factor |
(Rus)
|
| Vol 23, No 1 (2021) |
CLINICAL ONCOLOGY |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
(Rus)
(Eng)
|
| Vol 23, No 1 (2021) |
CLINICAL ONCOLOGY |
Antiangiogenic therapy for breast cancer with triple negative phenotype |
(Rus)
|
| Vol 23, No 4 (2021) |
CLINICAL ONCOLOGY |
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib |
(Rus)
|
| Vol 23, No 4 (2021) |
CLINICAL ONCOLOGY |
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III |
(Rus)
|
| Vol 26, No 1 (2024) |
Articles |
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study |
(Rus)
|
